請更新您的瀏覽器

您使用的瀏覽器版本較舊,已不再受支援。建議您更新瀏覽器版本,以獲得最佳使用體驗。

Eng

Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company

PR Newswire (美通社)

更新於 19小時前 • 發布於 20小時前 • PR Newswire

- First global out-licensing deal since founding — tangible return on new drug development investments

- Significant milestone payments and future revenue expected — additional out-licensing of proprietary technologies anticipated

SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- Dx&Vx (DXVX) has signed its first-ever global out-licensing agreement since its establishment.

On July 30, DXVX announced that it has entered into a co-development and license agreement valued at approximately USD 220 million with a U.S.-based biotech company for its mRNA-based cancer vaccine. Revenue sharing post-commercialization will be handled separately.

Through this agreement, DXVX will grant its partner exclusive global rights to its patented mRNA-based cancer vaccine. The partner company will pay DXVX a total of approximately USD 220 million in development milestones and, following commercialization, sales-based milestone payments exceeding 10% of cumulative sales over a period of more than 15 years. Given the vast size and growth potential of the global oncology and cancer vaccine markets and the expected market share, DXVX projects that post-commercialization sales milestone revenues could exceed USD 940 million.

Even after the out-licensing, DXVX will remain responsible for leading R&D activities necessary for commercialization, including preclinical studies, Phase 1–3 clinical trials, and production. The partner company will be responsible for global regulatory approvals and sales. Other specific terms remain confidential by mutual agreement.

The mRNA-based cancer vaccine covered under this license agreement is part of DXVX's proprietary pipeline and has demonstrated superior anticancer efficacy in preclinical animal studies compared to global competitors currently undergoing Phase 2b trials. DXVX has completed patent applications for the compound. In addition, the candidate utilizes DXVX's proprietary long-term ambient storage mRNA vaccine platform technology, securing a technological edge over competitors.

The partnering U.S. biotech company possesses RNA-based drug development and diverse platform technologies. Following their first partnering meeting at the JP Morgan Healthcare Conference and Biotech Showcase this January, the partner recognized DXVX's technological strengths, leading to the rapid conclusion of this agreement.

Kevin Kwon, CEO of DXVX, stated, "We are very pleased to sign our first global out-licensing agreement. We sincerely appreciate our partner's recognition of our technological strength," adding, "We believe this agreement will positively influence additional licensing discussions currently underway for other pipelines."

Meanwhile, DXVX's largest shareholder is Chong-Yoon Lim, Chairman of COREE and eldest son of the founder of Hanmi Pharmaceutical Group. In addition to the mRNA cancer vaccine, DXVX is developing several pipeline assets, including a long-term ambient storage mRNA vaccine platform, an oral anti-obesity therapeutic, and OVM-200, a peptide-based cancer vaccine, and other pipelines. The company is currently in licensing discussions with multiple domestic and international pharmaceutical and biotech companies.

查看原始文章

"HYAB Thematic Youth Internship Programmes to the Mainland - Youth Internship Programme at Dunhuang 2025" Achieves Remarkable Results

PR Newswire (美通社)

Technology Drives Creativity: Digital Domain Showcases R&D Achievements at WAIC 2025

PR Newswire (美通社)

AI visionaries converge in Shanghai to chart the future of innovation

PR Newswire (美通社)
查看更多
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

最新內容

China-Japan Premium Rice Tasting: China's Arowana WuChang Base Original Fragrant Rice Takes Top Prize

PR Newswire (美通社)

MTR* and Airport Express Advertising Presents "5G Summer Thrill"

PR Newswire (美通社)

Perennial Holdings, Lujiazui Administrative Bureau and Lujiazui Group Sign Strategic Partnership to Establish Shanghai's First Wholly Foreign-Owned Tertiary General Hospital

PR Newswire (美通社)

The Beauty of Doing Better: Why sustainability, storytelling, and scent still matter

Tatler Hong Kong

Tuniu to Report Second Quarter 2025 Financial Results on August 15, 2025

PR Newswire (美通社)

OpenWay recognized as Best-in-Class in Datos Insights' 2025 Matrix for Merchant Acquiring Platforms

PR Newswire (美通社)

Economic Watch: Eurozone's economy grows slightly as U.S. tariffs bite

XINHUA

China takes back home remains of 265 martyrs in Korean War in five years

XINHUA

Update: China's non-manufacturing PMI at 50.1 in July

XINHUA

HERALDING A REFINED NEW STANDARD IN COLLAGEN AESTHETICS

PR Newswire (美通社)

Agoda launches campaign to drive tourism as Singapore celebrates 60 years of independence

PR Newswire (美通社)

This 5,800 sq.ft. Abode on Tai Po Road Shines like a Jewellery Box

Home Journal

2,670 Sq.ft Camellia Avenue Abode Showcases a Soft Luxury Aesthetic

Home Journal

Inside a 1,388 Sq.ft Villa Lucca Apartment with Depth and Contrast

Home Journal

Chinese researchers develop satellite-based method to quantify global landfill methane emissions

XINHUA

Metalpha Reports a Nearly Tripled Revenue Surge & First Positive Annual Profit in FY2025

PR Newswire (美通社)

China identifies burial sites or finds relatives for 7,000 fallen soldiers

XINHUA

Fictional K-drama restaurants we’d visit, from Jeongje in ‘Tastefully Yours’ to Hungry Wok in ‘Wok of Love’

Tatler Hong Kong

ICAC concludes first-ever regional anti-corruption training for ASEAN youth and bolsters new graft fighting forces in Asia-Pacific

PR Newswire (美通社)

MetroTrans 2025: Premier Global Hub for Rail Transit Innovation and Collaboration

PR Newswire (美通社)

Xinhua News | U.S. Treasury Department imposes massive sanctions against Iranian shipping network

XINHUA

Xinhua News | Trump orders universal 50 pct tariff on imports of certain copper products

XINHUA

China Coast Guard patrols waters around Huangyan Dao

XINHUA

Golden rapeseed flowers blossom in Xinjiang's Zhaosu

XINHUA

A Mediterranean summer: La Petite Maison unveils seasonal menus

Tatler Hong Kong

OSOME AND ASPIRE EMPOWER FOUNDERS TO RECLAIM TIME WITH TECH-DRIVEN INNOVATION

PR Newswire (美通社)

Activeo Launches OneView CSM: A Seamless Bridge Between Contact Centres and ServiceNow Customer Service Management

PR Newswire (美通社)

TECNO Unveils CAMON 40 Series Sandy Titanium Edition, Fusing Luxurious Aesthetics with Cutting-Edge Technology

PR Newswire (美通社)

China's non-manufacturing PMI at 50.1 in July

XINHUA

Laos works to boost tourism as fuel for economic growth

XINHUA

Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC

PR Newswire (美通社)

Eddid Financial Granted SFC Approval to Upgrade In-Kind Subscription/Redemption Mechanism for Digital Asset spot ETFs

PR Newswire (美通社)

Adidas expects 200 mln euro tariff hit

XINHUA

IMF upgrades Malaysia's growth forecasts for 2025, 2026

XINHUA

"MMCA×LG OLED SERIES" KICKS OFF TO BRING DIGITAL ART CLOSER TO THE PUBLIC

PR Newswire (美通社)

Tongyu Launches "Satellite-Ship-Terminal" Integrated Maritime Solution, Ushering in New Era of Smart Maritime

PR Newswire (美通社)

Hong Kong shows strong competitiveness, emerges with new strengths: report

XINHUA

Thailand adjusts EV policy to ease production requirements, boost exports

XINHUA

Xinhua Commentary: Dialogue and mutual benefit key to long-term stability in China-U.S. trade ties

XINHUA

Roundup: China wins two silver, Marchand sets 200m individual medley world record at Singapore Worlds

XINHUA